Indeed, the first FDA-approved clinical trial for in-body CRISPR gene therapy was a treatment for inherited retinal disease by using AAV-derived vectors to target the deep-intronic c2991 + 1655A > G single nucleotide mutation in the CEP290 gene [14]. The gene discussed is CEP290; the disease is Abnormal retinal morphology.